Results 11 to 20 of about 23,919 (200)

In vitro Synergistic and Bactericidal Effects of Aztreonam in Combination with Ceftazidime/ Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam Against Dual-Carbapenemase-Producing Enterobacterales [PDF]

Infection and Drug Resistance
Ying Fu,1,2 Yufeng Zhu,1,3 Feng Zhao,1,2,4 Bingyan Yao,1,2 Yunsong Yu,5 Jun Zhang,1,2 Qiong Chen6 1Department of Clinical Laboratory, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People’s Republic of ...
Fu Y, Zhu Y, Zhao F, Yao B, Yu Y, Zhang J, Chen Q   +6 more
doaj   +2 more sources

Aztreonam: clinical and pharmacological characteristics at the present stage [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2023
One of the urgent problems of modern health care is the growing resistance of microorganisms to antibiotics, including carbapenems, which until recently were considered as the drugs of choice in the treatment of life-threatening infections.
Popov D.A., Zubareva N.A., Parshakov A.A.   +2 more
doaj   +1 more source

Direct Detection of Extended Spectrum β-Lactamases from Positive Blood Cultures by using Aztreonam and Clavulanate [PDF]

Journal of Clinical and Diagnostic Research, 2021
Introduction: Bacterial Sepsis by Multidrug Resistant Gram Negative Bacilli (MDRGNB) producing Extended Spectrum β-Lactamases (ESBL) is one of the major causes of mortality and morbidity in hospitals.
Renji Francis, Ambica Rangaiah, Kusuma Gowdra Rangappa, Shwetha Jinnahalli Venugopal   +3 more
doaj   +1 more source

In Vitro Evaluation of the Activity of Aztreonam-Avibactam against 341 Recent Clinical Isolates of Anaerobes

Microbiology Spectrum, 2021
Aztreonam-avibactam is under clinical development for multidrug-resistant Gram-negative infections. We evaluated in vitro activity against 341 recent clinical isolates.
David R. Snydman, Laura McDermott
doaj   +1 more source

Antimicrobial therapy of sepsis caused by carbapenem-resistant Klebsiella pneumoniae in patients with hematological malignancies [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2022
Objective. To compare the efficacy of ceftazidime-avibactam and aztreonam combination therapy with “standard” therapy in patients with hematological malignancies and sepsis, caused by carbapenemresistant K. pneumoniae. Materials and Methods.
Barantsevich N.E., Barantsevich E.P.
doaj   +1 more source

Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates

Microbiology Spectrum, 2021
Ceftazidime-avibactam (CZA) has emerged as a promising solution to the lack of new antibiotics against Pseudomonas aeruginosa infections. Data from in vitro assays of CZA combinations, however, are scarce. The objective of our study was to perform a time-
María M. Montero, Sandra Domene Ochoa, Carla López-Causapé, Sonia Luque, Luisa Sorlí, Núria Campillo, Inmaculada López Montesinos, Eduardo Padilla, Núria Prim, Ariadna Angulo-Brunet, Santiago Grau, Antonio Oliver, Juan P. Horcajada   +12 more
doaj   +1 more source

Case report: Continuous infusions of ceftazidime-avibactam and aztreonam in combination through elastomeric infusors for 12 weeks for the treatment of bone and joint infections due to metallo-β-lactamase producing Enterobacterales

Frontiers in Medicine, 2023
Among carbapenem-resistant Enterobacterales, metallo-beta-lactamase producing strains represent a growing therapeutic challenge. While the association of aztreonam and ceftazidime-avibactam has been investigated in recent years for the treatment of ...
Yanis Merad, Anne Conrad, Anne Conrad, Anne Conrad, Anne Conrad, Sophie Brosset, Sophie Brosset, Axel Schmidt, Axel Schmidt, Camille Hanriat, Camille Hanriat, Sebastien Lustig, Sebastien Lustig, Sebastien Lustig, Frederic Laurent, Frederic Laurent, Frederic Laurent, Frederic Laurent, Camille Kolenda, Camille Kolenda, Camille Kolenda, Camille Kolenda, Tiphaine Roussel-Gaillard, Tiphaine Roussel-Gaillard, Tiphaine Roussel-Gaillard, Cecile Batailler, Cecile Batailler, Cecile Batailler, Tristan Ferry, Tristan Ferry, Tristan Ferry, Tristan Ferry, Lyon BJI Study group   +32 more
doaj   +1 more source

Evaluation of Aztreonam and Ceftazidime/Avibactam Synergism against Klebsiella pneumoniae by MALDI-TOF MS

Antibiotics, 2023
Introduction: Resistance to carbapenems due to the co-production of NDM and ESBL or NDM and KPC is increasing. Therefore, combined therapy with aztreonam (ATM) plus ceftazidime/avibactam (CZA) has been recommended.
Camila Mörschbächer Wilhelm, Everton Inamine, Andreza Francisco Martins, Afonso Luís Barth   +3 more
doaj   +1 more source

Antimicrobial Activity of Aztreonam in Combination with Old and New β-Lactamase Inhibitors against MBL and ESBL Co-Producing Gram-Negative Clinical Isolates: Possible Options for the Treatment of Complicated Infections

Antibiotics, 2021
Metallo-β-lactamases (MBLs) are among the most challenging bacterial enzymes to overcome. Aztreonam (ATM) is the only β-lactam not hydrolyzed by MBLs but is often inactivated by co-produced extended-spectrum β-lactamases (ESBL).
Gianluca Morroni, Raffaela Bressan, Simona Fioriti, Gloria D’Achille, Marina Mingoia, Oscar Cirioni, Stefano Di Bella, Aurora Piazza, Francesco Comandatore, Carola Mauri, Roberta Migliavacca, Francesco Luzzaro, Luigi Principe, Cristina Lagatolla   +13 more
doaj   +1 more source

Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Enterobacterales Analyzed by ICU and Non-ICU Wards, Infection Sources, and Geographic Regions: ATLAS Program 2016–2020

Antibiotics, 2023
Increasing antimicrobial resistance among multidrug-resistant (MDR), extended-spectrum β-lactamase (ESBL)- and carbapenemase-producing Enterobacterales (CPE), in particular metallo-β-lactamase (MBL)-positive strains, has led to limited treatment options ...
Denis Piérard, Elizabeth D. Hermsen, Michal Kantecki, Francis F. Arhin   +3 more
doaj   +1 more source